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Theroleofbridgingtherapies forpatientswithhepatocellularcarcinoma(HCC)onthewaitinglist for
liver transplantation (LT) remains controversial. There is strong evidence to support the effectiveness
of sorafenib in extending the time to progression of HCC. Using a Markov model, we compared two
strategies: one using sorafenib as neoadjuvant therapy before LT (Strategy A), and the other using no
bridgingtherapyinthefirst6months(StrategyB).Referencecase:T2HCCpatientwithcompensated
cirrhosis. The benefit of sorafenib in delaying time to HCC progression was expressed as the hazard
ratio (HR) and taken from recently published randomized trials. The endpoints considered were:
survivalbenefitmeasured inquality-adjusted lifedays (QALDs), transplantprobability, costs (C) in€,
willingness to pay (WTP), and net health benefit (NHB), where NHB  survival benefit  C/WTP.
The calculated WTP of sorafenib in Italy was 346 € per QALD. Probabilistic sensitivity analysis
showed a median survival benefit of 94 QALDs (10% percentile  38, 90% percentile  210). In the
base-case scenario (HR0.47,monthlydropoutprobability5%,mediantimetoLT3months),
the gain in LT probability due to sorafenib was 5% and it increased proportionally with increasing
median times to LT and decreasing HR. In the cost-benefit analysis, the incremental NHB of Strategy
A versus Strategy B was 37 QALDs; it increased as sorafenib HR decreased and when median times to
LT were shorter than 6 months, whereas for longer times it gradually dropped, particularly when
Strategy B included effective locoregional treatments. Conclusion: Sorafenib neoadjuvant therapy is
cost-effective by comparison with no therapy for T2-HCC patients waiting for LT, particularly for
median times to LT under 6 months. (HEPATOLOGY 2010;51:165-173.)
See Editorial on Page 12
Due to the disparity between organ availability anddemand, dropout while on the waiting list (WL)has become the main predictor of survival for adult
patients awaiting liver transplantation (LT) for malignant or
nonmalignant (NM) chronic liver disease when an inten-
tion-to-treat analysis is applied.1-3 Tumor progression before
LT was the main reason for removing patients with hepato-
cellular carcinoma (HCC) meeting the Milan criteria (MC)4
from the WL, whereas for NM patients the main reason was
the patient’s death due to complicated cirrhosis.3,5
A first way to contain this considerable dropout risk is
to proportionally increase the probability of transplanta-
tion for patients with more severe liver disease by adopt-
ing specific prioritization policies. This is the primary
strategy used by the US liver allocation system, which has
adopted the model for endstage liver disease (MELD) in
recent years to establish which HCC and non-HCC pa-
tients take priority for transplantation.6
For HCC patients, the dropout risk might also be re-
duced by treating the tumor in order to slow its progres-
sion. Locoregional treatments, such as resection, ablation
(percutaneous or laparoscopic), and transarterial chemo-
embolization (TACE) have been proposed as neoadjuvant
therapies before LT.7-9
Although these procedures have a well-established ef-
ficacy in prolonging the survival of HCC patients,10 no
studies strongly support and exactly measure their effec-
tiveness in reducing the risk of dropout among HCC
patient candidates for LT.11 This is the main reason why
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recent guidelines have prudently suggested that locore-
gional bridging therapies “can be considered” only if the
median time on the WL exceeds 6 months.10
A new systemic, molecularly targeted therapy, sor-
afenib, was recently tested in two large Phase 3 random-
ized clinical trials (RCTs), showing a significant efficacy
in delaying tumor progression12,13 in patients with inter-
mediate-advanced HCC. This effect was maintained in
demographically different study populations, as demon-
strated by the similar hazard ratios (HRs) in the two
RCTs. Unlike the case of locoregional therapies, there-
fore, the efficacy of sorafenib in slowing tumor progres-
sion has been demonstrated and quantified with the
highest level of scientific evidence. On the other hand,
such a powerful antiangiogenic effect as that of sorafenib
may interfere with vessel repair and thus give rise to a
potentially higher risk of postsurgical complications, es-
pecially in the case of unscheduled measures such as trans-
plantation. There are no data, however, to demonstrate
and measure this potential toxicity of sorafenib in surgical
patients.
In the present study, we hypothesized that by delaying
tumor progression sorafenib could decrease dropout from
the transplant WL and thus increase the number of pa-
tients able to be transplanted. We developed a Markov
model to represent and quantify the potential cost-benefit
ratio of sorafenib as a neoadjuvant therapy for HCC pa-
tients meeting the MC and awaiting LT. It has to be
emphasized, however, that this model was designed while
awaiting robust data on the safety of sorafenib.
Patients and Methods
Definitions and Endpoints. The study focused on
HCC candidates for LT meeting the MC (Fig. 1). As a
reference case, our model considered a patient with com-
pensated cirrhosis14 and a T2 tumor,15 i.e., one nodule
2-5 cm or 2-3 nodules 3 cm. The effect of a generic
neoadjuvant therapy on time to progression was expressed
in our model in terms of HR, as in recent RCTs.12,13 In
the particular context of the WL before LT, we considered
this HR value as a linear factor for correcting the conven-
tional dropout probability (DP) of HCC patients await-
ing LT. Thus, for example, if the monthly conventional
DP for HCC patients was 4% and the treatment HR was
0.50, then their treatment-modified dropout probability
(SDP) became 4% * 0.50  2% according to the follow-
ing formula: SDP  HR * DP.
Although there are no robust studies measuring the
efficacy of locoregional therapies in terms of reducing the
risk of dropout, because we know the exact HR of sor-
afenib in extending the time to progression of HCC the
aim of this study was to compare two strategies: one using
sorafenib as a neoadjuvant therapy before LT (Strategy
A), and one with no bridging therapies (Strategy B). In
current clinical practice, however, patients likely to have
to wait some time and not given priority are treated al-
most everywhere. For this reason our model also included
a specific sensitivity analysis considering the potential in-
troduction of locoregional therapies in Strategy B patients
when their median time on the WL exceeded 6 months.
Starting from these assumptions, we considered four
endpoints to quantify the potential benefits of sorafenib
neoadjuvant therapy:
1. Gain in transplant probability. The main assump-
tion of this study is that, by delaying tumor progression,
sorafenib could decrease dropout from the transplant WL
and thus increase the number of patients able to be trans-
planted.
2. Survival benefit. The utility of each strategy was
measured in terms of quality-adjusted intention-to-treat
survival and this was expressed in quality-adjusted life
days (QALDs). We also measured the proportional de-
crease in transplant priority for Strategy A patients that
was needed to balance the utility of the two strategies.
3. Marginal cost-utility ratio. We considered as funda-
mental cost-utility outcome measure the ratio between
costs and QALDs, characterizing each strategy in each
particular scenario. The difference between these calcu-
lated values (Strategy A cost/utility  Strategy B cost/
utility) was the marginal cost-utility ratio.
4. Incremental net health benefit (NHB). The NHB
of an alternative treatment is calculated using the formula
(16): NHB  U  C / WTP, where U is the utility, C is
the cost, and WTP is the willingness to pay. WTP is
represented by the ratio of the mean incremental cost to
the mean incremental effectiveness (utility). In the
Fig. 1. The event pathway: decision tree and states of health.
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present study the WTP was defined as the cost per QALD
gained that society has already accepted as being cost-
effective for a patient treated with sorafenib. Given a par-
ticular WTP value, the difference between the NHBs of
the two strategies is defined as the “incremental NHB.”
Model Assumptions and Variables. We constructed
a Markov model, which examines the decision whether or
not to use sorafenib as neoadjuvant therapy before LT.
We hypothesized that therapy with sorafenib started at
the time of listing. Moreover, as in the Sharp trial and in
Italian clinical practice, therapy with sorafenib was
stopped once patients have tumor progression. Thus,
Strategy A had the potential benefits of sorafenib therapy
only during the WL (and not after dropout), whereas
Strategy B benefited from sorafenib therapy only after
dropout from the WL in patients with advanced HCC
and compensated cirrhosis. Moreover, our model takes
into account the risk of decompensation in patients with
compensated cirrhosis.13 We assumed that sorafenib ther-
apy was administered only to patients with a compensated
cirrhosis.
In constructing the model, we made several assump-
tions based on data available in the literature17-24 or justi-
fiable clinical opinions (Table 1).
WL Variables. The dropout probability from the
WL of our reference HCC case receiving no bridging
therapies (Strategy B) was calculated from four major
studies,17-20 and this probability was confirmed in re-
cent data from the UNOS database,6,21,22 where only a
minority of patients had locoregional bridging thera-
pies and the median time to LT was relatively short.
The median time to transplant was used, rather than
the median time on the WL, to calculate the daily
probability of getting a transplant, as in other recent
models,21,22 because the latter excludes the time spent
on the list with an inactive status.
As mentioned above, we assumed that the conven-
tional dropout probability of HCC patients was modified
linearly by the specific sorafenib HR on time to progres-
sion.11,12 In the base-case scenario, we assumed an HR 
0.47, which is the value obtained in subgroup analyses on
the efficacy of sorafenib for intermediate HCCs.23
Table 1. Variables Used to Construct the Model
Variables Base-Case Analysis Range Tested Source
PRETRANSPLANT VARIABLES
Median time to transplant (days) HCC (meeting Milan) 90 32–145 (6, 21)
Dropout probability for HCC progression per month 5% 4–6% (17–19)
Sorafenib hazard ratio for tumor progression 0.47 0.23–0.93 (23)
Compensated cirrhosis (2-year survival rate) 90% 70–100% (14)
Decompensated cirrhosis (2-year survival rate) 50% 40%–60% (14)
Annual probability of transition from compensated to decompensated 0.07 0.05–0.10 (14)
Treated BCLC stage B median survival (months) 20 19–21 (24,25)
Treated BCLC stage C median survival (months) 10 9–11 (24,25)
Untreated BCLC stage C median survival 7 6–8 (24, 25)
BCLC stage D median survival (months) 4 3–5 (24, 25)
Pretransplant quality-of-life utility 0.53 0.45–0.6 (21)
POSTTRANSPLANT VARIABLES
Transplant-related operative death 5% 2–8% (21)
Posttransplant survival (probability/5 years) 72% 70–75% (21)
Posttransplant quality-of-life utility 0.62 0.61–0.63 (21)
VARIABLES FOR COST ANALYSIS
Follow-up while awaiting LT (€/day) 100 70–120 N/A
Sorafenib while awaiting LT (€/day) 150 100–200 N/A
Percutaneous ablation (€) 7000 6000–8000 N/A
Chemo-embolization (€) 3300 3000–4000 N/A
Sorafenib after dropout (€/day) 150 100–200 N/A
Follow-up after dropout (€/day) 120 90–150 N/A
Transplantation (€) 80000 60000–100000 N/A
Follow-up therapy after transplantation (€/day) 50 40–60 N/A
VARIABLES FOR CALCULATING WTP IN ITALY
Cost of each Sorafenib capsule (€) 50 N/A N/A
Median duration of treatment (months) 5.3 0.2–16.1 (12)
Proportion receiving more than 80% of daily dose 76% N/A (12)
Sorafenib group median survival (months) 10.7 N/A (12)
Placebo group median survival (months) 7.9 N/A (12)
Time horizon (years) 10 5–15 N/A
Abbreviations: HCC, hepatocellular carcinoma; BCLC, Barcelona Clinic Liver Cancer; WL, waiting list; LT, liver transplantation; WTP, willingness to pay.
HEPATOLOGY, Vol. 51, No. 1, 2010 VITALE ET AL. 167
Because there are no robust data in the literature on the
tumor stage of WL patients at the moment of dropout, in
our model we assumed that patients with compensated
cirrhosis removed from the WL due to tumor progression
were Barcelona clinic liver cancer (BCLC) B and C pa-
tients in equal proportions, whereas those with decom-
pensated cirrhosis and tumor progression were assumed
to be in BCLC D stage. According to recently published
guidelines,24,25 patients with compensated cirrhosis and a
tumor progressing beyond the MC (BCLC B and C pa-
tients) should be treated with chemoembolization (stan-
dard care for BCLC B patients) or sorafenib (standard
care for BCLC C patients). We assumed that the BCLC B
patients had a mean of three TACE treatments, whereas
the BCLC C patients were given systemic therapy with
sorafenib. As reported in recent studies,11,12,24,25 we set
the median survival of treated patients at 20 months for
BCLC B patients, and 10 months for BCLC C patients
(Table 1). As mentioned above, we assumed that Strategy
A patients developing a BCLC C tumor after dropout did
not receive further sorafenib therapy. We set the median
survival of untreated BCLC C patients at 7 months,
whereas that of untreated BCLC D patients at 4
months.11,12,24,25 In the sensitivity analysis simulating the
introduction of locoregional treatments in Strategy B pa-
tients after the first 6 months on the WL, we assumed that
patients underwent one percutaneous ablation and one
TACE.
Posttransplant Variables. As in recently published
Markov models,16,17 we considered an early transplant-
related mortality of 5% and a long-term 5-year survival
rate of 72% for patients transplanted for HCC meeting
the MC.
Variables for Cost Analysis. Our analysis included
all direct health-related costs (in Euros in 2008) associated
with each strategy, assessed from a payer’s perspective and
discounted at 3% a year.15
The costs were obtained from the current payments
within the Italian public health care system. Table 1 sum-
marizes our hospital’s mean variable costs for each proce-
dure.
Indirect costs, such as lost earnings due to poor health,
were not estimated. In Italy the cost of each sorafenib
capsule is around €50. Because not all patients are able to
receive the whole therapeutic dose (four capsules/day),
from the proportion of patients receiving more than 80%
of the planned daily dose in the Sharp trial11 we calculated
a median three capsules for each day of treatment, for each
patient treated both on the WL and in BCLC stage C
(after removal from the WL). For HCC patients removed
from the WL due to tumor progression (patients with
BCLC stages B and C), we also considered a minimum
follow-up cost for palliative care.
Calculation of the WTP for Sorafenib in Italy.
Sorafenib therapy and its related costs have been accepted
in Italy on the strength of the results of the Sharp trial.11
In a Markov model specifically designed to calculate
WTP, we therefore included the results of the Sharp trial
and the cost per capsule accepted by the Italian public
health system (Table 1).
Considering a median 5 months of time on the treat-
ment,11 and a median number of three capsules/day,11 we
calculated a median overall cost of the sorafenib therapy
per patient at €22,500.
From the median survival times for the sorafenib and
placebo groups in the Sharp trial (10.7 and 7.9 months,
respectively), and using the pre-LT quality of life utility
for HCC patients,21 we calculated a crude utility of sor-
afenib therapy of 65 QALDs, so the calculated WTP was
€346 per extra day of life.
Follow-up and Quality of Life Utilities. Patients
were followed up for 10 years in the model, including
periods before and after transplantation. The length of the
Markov cycle was 1 day, and survival was adjusted for
quality of life, based on specific utilities. Annual and
monthly probabilities were converted into daily probabil-
ities using a linear decay function.15 Quality of life was
determined for pre- and posttransplant patients by means
of a systematic review of the literature, as described else-
where.16,17 We assumed the same utility for all HCC pa-
tients before LT whatever their tumor stage. Quality-
adjusted life expectancy was discounted at a rate of 3% a
year. All analyses were performed using the TreAge
Prov2009 (TreAge Software, Williamstown, MA).
Sensitivity Analysis. A Monte Carlo probabilistic
sensitivity analysis was used to understand the impact of
variable uncertainties on the model results and to estimate
the confidence that can be placed in analyzing such re-
sults. We assumed that the distribution of each variable
included in our model followed a beta distribution. More-
over, we set the number of distribution samples of the
Monte Carlo simulation at 1,000.
For descriptive purposes, we performed conventional
one- and two-way sensitivity analyses to show the corre-
lation between the study endpoints and specific crucial
variables (sorafenib HR and median time to LT).
As mentioned above, moreover, we performed a spe-
cific sensitivity analysis simulating the introduction of
locoregional therapies after the first 6 months on the WL
for Strategy B patients. In particular, the model assumed
that the application of conventional bridging therapies
prompted a constant decrease in the dropout risk for
HCC patients. In the sensitivity analysis we calculated the
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value of this HR (due to locoregional therapies) that was
needed to balance the benefit of sorafenib neoadjuvant
therapy.
Results
Survival Benefit and Transplant Probability. To
take into account the impact of variable uncertainties on
the model results we performed a Monte Carlo probabi-
listic sensitivity analysis. According to this analysis, the
median utility of Strategy A was 1,350 QALDs (10%
percentile  1,151, 90% percentile 1,434), whereas the
median utility of Strategy B was 1,244 QALDs (10%
percentile  978, 90% percentile  1,368). In Fig. 2 the
distribution of incremental QALD gains of Strategy A
versus Strategy B are represented: Strategy A showed a
median survival benefit versus Strategy B of 94 QALDs
(10% percentile  38, 90% percentile  210).
In the base-case analysis (Table 1), the strategy involv-
ing sorafenib treatment for HCC patients with a T2 tu-
mor and compensated cirrhosis increased the probability
of having a transplant by 5% with respect to no treatment
(from 47% to 52%) if a time horizon of 10 years was
considered. As a consequence, the same strategy reduced
the individual risk of death by 5%, from 53% (for Strat-
egy B) to 48% (for Strategy A). This lower mortality risk
coincided with a gain of 89 QALDs for each patient
treated.
In our utility-gain model, we performed one-way sen-
sitivity analysis for all variables (Table 1). The variables
most affecting the gain in LT probability and survival
benefit were the HR (expressing the ability of sorafenib to
delay tumor progression) and the median time to LT, as
shown in Fig. 3.
As Fig. 3A clearly shows, higher median times to LT
corresponded to a greater gain in transplant probability of
Strategy A versus Strategy B, and this prognostic relation-
ship had a clearly linear behavior. The angular coefficient
of this relationship, on the other hand, was strongly in-
fluenced by the particular sorafenib HR. The median
time to LT and sorafenib HR also had a considerable
influence on survival benefit (Fig. 3B), but this effect was
almost logarithmic rather than linear.
In Fig. 4 we evaluated the impact of the sorafenib HR
on the transplant prioritization (expressed as the trans-
plant probability ratio) of HCC patients on the WL. We
found an almost linear relationship between the sorafenib
HR on time to tumor progression and the ratio applied to
transplant probability. According to this relationship,
therefore, our model found that the effect of sorafenib on
tumor progression can be used to proportionally reduce
the priority of HCC patients without impairing their in-
tention-to-treat survival rate.
Cost-Utility and Cost-Benefit Analyses. In the base-
case analysis, the marginal cost-utility ratio of Strategy A
Fig. 2. Monte Carlo probabilistic sensitivity analysis: distribution of
incremental gains in QALDs of Strategy A (with sorafenib before LT)
versus Strategy B (without sorafenib before LT).
Fig. 3. Gain in LT probability (A) and in QALDs (B) of sorafenib
neoadjuvant therapy as a function of sorafenib effect (HR) on time to
progression of HCC (stratification subgroups) and median time to trans-
plant (main x axis).
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versus Strategy B was €197 per QALD, whereas the in-
cremental NHB (assuming WTP  €346 per QALD)
was 37 QALDs. Figure 5 shows that the marginal cost-
utility ratios of Strategy A / Strategy B correlated strongly
with the median times to LT and the sorafenib HR, but
these ratios were below the calculated WTP value in the
majority of cases. In particular, we found an inverse rela-
tionship between these two variables, i.e., the longer the
median time to LT, the lower the HR threshold had to be
in order to balance the utility against the costs.
One-way sensitivity analyses (Fig. 6) confirmed that,
using the calculated WTP value, the incremental NHB of
Strategy A versus Strategy B increased as the sorafenib HR
decreased (Fig. 6A) and the threshold value of HR where
Strategy A became harmful was 0.75.
The incremental NHB tended to rise for median times
to LT below 6 months (Fig. 6B), whereas it dropped for
longer waiting times and only became negative more than
24 months after starting the neoadjuvant therapy.
As expected, the incremental NHB of sorafenib
dropped more rapidly when locoregional therapies were
introduced after the first 6 months on the WL (Fig. 7).
For example, sorafenib maintained a positive NHB up to
12 months on the WL only when the impact (HR) of
conventional therapies on the dropout rate was higher
than 0.5 (Fig. 7).
Discussion
To the best of our knowledge, this is the first study to
analyze the neoadjuvant role of sorafenib in the context of
LT for HCC patients. Monte Carlo probabilistic sensitiv-
ity analysis showed with a high level of confidence (Fig. 2)
that neoadjuvant therapy with sorafenib before LT had a
beneficial effect on survival with respect to a strategy with-
out therapy. This central result of our study may be es-
sentially explained by the positive impact of sorafenib on
the transplant probability of HCC patients listed for LT
(Fig. 2A). Our data confirmed previous findings concern-
ing other Markov models of pre-LT bridging therapies.18
Fig. 4. Sensitivity analysis demonstrating the potential impact of the
antitumoral effect of sorafenib (sorafenib HR) on patient transplant
prioritization (transplant probability ratio). The transplant probability ratio
threshold is the intersection between the black and white areas and
equals the ratio at which the benefit of sorafenib on tumor progression
is outweighed by the harm caused by a corresponding decrease in the
patient’s priority for transplantation.
Fig. 5. Marginal cost-utility ratios afforded by Strategy A versus
Strategy B as a function of median time to LT and sorafenib HR.
Fig. 6. Incremental NHB between the two strategies according to
sorafenib HR (A) and median time to transplant (B).
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The results of the present study are very strong, however,
because they are the first to be based on the findings of two
RCTs.12,13 In fact, whereas locoregional therapies such as
TACE, percutaneous ablation, or resection7-9 have been
recommended to reduce the dropout risk for HCC can-
didates awaiting LT, the scientific evidence to support
and quantify their efficacy against tumor progression re-
mains weak,11 especially as concerns the first 6 months on
the WL.10,18 For the same reason, however, it is extremely
important to emphasize that the results of this study can-
not be used to promote sorafenib as a first-line neoadju-
vant strategy for HCC patients awaiting LT. In fact,
locoregional therapies have a well-known relevant impact
on the survival of early HCC patients, so they are proba-
bly more powerful bridging strategies (when properly in-
dicated). The basic assumption of this study is that we
know the effect of sorafenib (HR) on time to progression,
but the same cannot be said of conventional bridging
therapies. On these grounds it is structurally impossible to
use this model to draw any direct comparisons between
sorafenib and locoregional therapies (resection, percuta-
neous ablation, or TACE) as bridging strategies. On the
other hand, the relationship between sorafenib and stan-
dard locoregional therapies that emerges from this study
may have two facets:
1. While awaiting more robust data on the efficacy of
locoregional therapies in delaying tumor progression, our
model may be used to assess the utility of sorafenib as a
neoadjuvant therapy before LT, and also as a more general
tool for studying the role of bridging therapies, taking
sorafenib as a “paradigm” due to its well-known, evi-
dence-based beneficial effect on tumor progression.12,13
2. The “no bridging therapy” strategy before LT is
now accepted by many centers around the world that
assign HCC patients high priority for LT.6 In this light,
the results of this study can easily be transposed to clinical
situations where HCC patients have low median waiting
times before they receive a transplant. In real life, how-
ever, when HCC patients have prospects of longer wait-
ing times (generally longer than 6 months) they are given
locoregional bridging therapies almost everywhere. That
is why our model also included a specific sensitivity anal-
ysis considering the potential introduction of locore-
gional therapies in Strategy B patients when their median
time on the WL exceeded 6 months (Fig. 7). We took the
HCC patient with a T2 tumor for reference in this study
because, among the candidates meeting the Milan crite-
ria, these characteristics identify a higher dropout risk.17
On these grounds, many centers around the world at-
tribute to T2 HCC patients 22 arbitrary points on the
MELD score to contain the risk of tumor progression by
reducing their waiting times. An excessive prioritization
carries the risk of underestimating the biological aggres-
siveness of liver tumors,10 however, or of harming the
competing NM transplant candidates at high risk of early
WL mortality (MELD score 20). Similarly, the higher
transplant probability due to sorafenib (Fig. 3A) risks be-
ing beneficial for treated HCC patients but harmful for
patients denied the chance of a transplant. From a popu-
lation utility perspective, therefore, the individual gain in
life expectancy thanks to sorafenib neoadjuvant therapy
could seem irrelevant. Nonetheless, the availability of pre-
dictive models21 that exactly correlate treatment efficacy
with gain in transplant probability and survival benefit
represents a potentially relevant tool for adapting the
transplant priority of individual patients to a given local
WL (relative proportions of HCC patients with T2 tu-
mors and NM patients with high MELD scores).
We found a linear correlation between sorafenib HR
and the transplant priority of HCC patients (Fig. 4); in
this context, a second potential benefit of sorafenib neo-
adjuvant therapy might be its use as a corrective factor of
HCC patient transplant priority in favor of NM patients
with high MELD scores (Fig. 4). A minimum WL period
maintaining a low risk of tumor progression (using sor-
afenib as bridging therapy), therefore, could be beneficial
both for HCC and NM transplant candidates.
This favorable scenario changes dramatically when we
consider the results of the cost-utility analysis, however.
In fact, marginal cost-utility ratios increased in our model
for longer times to LT or higher HR values (Fig. 4), which
means that the costs of sorafenib therapy increased more
rapidly than its utility according to these variables. Our
study confirmed that traditional cost-effectiveness analy-
Fig. 7. Sensitivity analysis demonstrating the potential impact of
introducing locoregional therapies after the first 6 months on the WL for
Strategy B patients. The threshold of the locoregional therapies HR is the
intersection between the black and white areas and equals the HR at
which the benefit of sorafenib on Strategy A patients is outweighed by the
benefit of locoregional therapies on Strategy B patients.
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ses cannot answer the underlying moral and policy issues
raised by expensive treatments, such as molecular targeted
therapies.26,27 To evaluate the threshold cost-utility of our
strategy, therefore, we referred to the accepted cost-utility
of sorafenib therapy in Italy, based on the results of the
Sharp trial. This seemed reasonable in terms of an ethical
concept of equity between patients with the same cancer,
and given that the proportion of early-stage HCC candi-
dates for LT is far lower than that of patients with inter-
mediate or advanced tumors.
The WTP obtained was used to calculate the incre-
mental NHB of Strategy A versus Strategy B. When this
cost-utility reference was introduced, the sorafenib neo-
adjuvant strategy became cost-effective in almost all clin-
ical scenarios tested in our Markov model (Figs. 4, 5).
Moreover, the incremental NHB was mainly concen-
trated in the first 6 months on the WL, i.e., the period
during which bridging therapies are currently not recom-
mended.10,18 Our findings, thus, suggest that different or
combined bridging therapies might be adopted, depend-
ing on the median time to LT in a given area. In fact, the
incremental NHB of Strategy A dropped faster when lo-
coregional therapies were included in Strategy B (Fig. 7)
according to current guidelines.10 In such a clinical sce-
nario, our specific sensitivity analysis supports the use of
sorafenib mainly for HCC patients with median waiting
times up to 12 months (Fig. 7).
There are some issues that might make our results un-
der- or overestimate the actual benefit of sorafenib before
LT. The actual benefit may be underestimated for two
main reasons: (1) because a declining trend in the sor-
afenib HR on time to progression has been demonstrated
from advanced to intermediate stage disease,23 the actual
HR range of sorafenib for T2 tumors may plausibly be
lower than was assumed in our model; and (2) sorafenib
acts on the molecular pathways promoting tumor dedif-
ferentiation and microscopic vascular invasion,25 but in
this study we did not consider the potential benefit of
sorafenib due to its effect on the tumor’s biological aggres-
siveness before LT and thus on the post-LT risk of tumor
recurrence.
The actual benefit of sorafenib before LT might be
overestimated, on the other hand, because the antiangio-
genic effect of sorafenib might have a negative effect on
the outcome of surgery, although such a negative effect
has never been demonstrated in the literature. This po-
tentially toxic effect may also be more relevant in trans-
plant candidates due to the unscheduled nature of LT
(making it impossible to prudently suspend sorafenib
some days before surgery) and to the presence of arterial,
venous, and biliary anastomoses at risk of leakage or
thrombosis. Only specifically designed clinical trials will
provide definitive data on these issues. While awaiting
such data, all the findings of this study must be considered
with great caution and cannot be transferred to daily clin-
ical practice.
In conclusion, sorafenib neoadjuvant therapy is cost-
effective by comparison with no therapy for T2-HCC
patients waiting for LT, particularly for median times to
LT under 6 months. This Markov decision analysis,
therefore, strongly supports the need for designing clini-
cal trials in this complex field to comprehensively study
the safety profile of sorafenib used before LT.
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